SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Yagoda A,Abi-Rached B,Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol. 1995; 22: 4260.
  • 2
    Lilleby W,Fossa SD. Chemotherapy in metastatic renal cell cancer. World J Urol. 2005; 23: 175179.
  • 3
    Motzer RJ,Bander NH,Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996; 335: 865875.
  • 4
    Coppin C,Porzsolt F,Kumpf J, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1: CD001425; 2005.
  • 5
    Medical Research Council Renal Cancer Collaborators: Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999; 353: 1417.
  • 6
    Pyrhonen S,Salminen E,Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999; 17: 28592867.
  • 7
    Kriegmair M,Oberneder R,Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology. 1995; 45: 758762.
  • 8
    Steineck G,Strander H,Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol. 1990; 29: 155162.
  • 9
    Negrier S,Escudier B,Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med. 1998; 338: 12721278.
  • 10
    Negrier S,Gomez F,Douillard JY, et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. World J Urol. 2005; 23: 161165.
  • 11
    Green S,Liu PY,O'Sullivan J. Factorial design considerations. J Clin Oncol. 2002; 20: 34243430.
  • 12
    Freedman LS. Tables of the number of patients required in clinical trials using the log rank test. Stat Med. 1983; 1: 121129.
  • 13
    Miller AB,Hoogstraten B,Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981; 47: 207214.
  • 14
    Common Toxicity Criteria version 2.0. Bethesda, Md: National Institutes of Health, National Cancer Institute; March 1998.
  • 15
    Aaronson NK,Ahmedzai S,Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365376.
  • 16
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 17
    Peto R,Pike MC,Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 139.
  • 18
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B. 1972; 34: 187202.
  • 19
    Schemper M,Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17: 343346.
  • 20
    Fayers PM. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer. 2001; 37: 13311334.
  • 21
    Therneau T,Grambsch P. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2000.
  • 22
    Neoptolemos JP,Stocken DD,Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 12001210.
  • 23
    Rosenberg SA,Lotze MT,Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316: 889897.
  • 24
    Yang JC,Sherry RM,Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21: 31273132.
  • 25
    McDermott DF,Regan MM,Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 133141.
  • 26
    Atzpodien J,Kirchner H,Illiger HJ, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer. 2001; 85: 11301136.
  • 27
    Henriksson R,Nilsson S,Colleen S, et al. Survival in renal cell carcinoma—a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer. 1998; 77: 13111317.
  • 28
    Lummen G,Goepel M,Mollhoff S, et al. Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma. J Urol. 1996; 155: 455458.
  • 29
    Atzpodien J,Kirchner H,Jonas U, et al. Interleukin-2 - and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 2004; 22: 11881194.
  • 30
    Boccardo F,Rubagotti A,Canobbio L, et al. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial. Tumori. 1998; 84: 534539.
  • 31
    Atzpodien J,Schmitt E,Gertenbach U, et al. Adjuvant treatment with interleukin-2 - and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005; 92: 843846.
  • 32
    Clark JI,Atkins MB,Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. JClin Oncol. 2003; 21: 31333140.
  • 33
    Pizzocaro G,Piva L,Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001; 19: 425431.
  • 34
    Porzsolt F. Adjuvant therapy of renal cell cancer with interferon alpha-2a [abstract]. Proc Am Soc Clin Oncol. 1992; 11: 202. Abstract 622.
  • 35
    Messing EM,Manola J,Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003; 21: 12141222.